EN
IT
Pink October: Genomica joins the month dedicated to breast cancer prevention
Dear Customer,
Pink October represents a valuable opportunity to strengthen cancer prevention and update clinical practice according to the most recent sector guidelines (AIOM and NCCN).
The international guidelines (NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, v.1.2026) highlight the importance of extending genetic testing beyond BRCA1/2, including other genes with high clinical impact. Alterations in these genes are associated with a significant increase in cancer risk and have direct implications for surveillance and prevention.
Among the most relevant:
đź“ŤPALB2: breast cancer risk comparable to BRCA2.
đź“ŤPTEN: associated with Cowden syndrome, with high breast cancer risk.
đź“ŤBRIP1: correlated with increased ovarian cancer risk.
The most recent AIOM recommendations also emphasize that the screening methodology for cancer susceptibility must allow the detection of both point variants and genomic rearrangements of BRCA1 and BRCA2.
These rearrangements, not identifiable by NGS alone, represent about 10–15% of pathogenic variants. Integration with the MLPA technique, in case of a negative first-level NGS test, is therefore essential to ensure a complete genetic diagnosis.
Throughout the month of October, on the occasion of the breast cancer prevention campaign, GENOMICA offers the possibility to perform the OncoAdvance Risk BRCA Plus test at a special discounted price.
OncoAdvance Risk BRCA Plus analyzes the following genes: BRCA1, BRCA2, PALB2, PTEN, BRIP1.
Study of BRCA1 and BRCA2 rearrangements with MLPA technique
In the event of a negative OncoAdvance Risk BRCA Plus test result, it is possible to integrate the analysis of BRCA1 and BRCA2 rearrangements with the MLPA technique.
This strategy makes it possible to offer patients a complete genetic evaluation in line with the most recent recommendations, ensuring optimized prevention and management pathways also for at-risk family members.
The choice of genes to be analyzed must be guided by an accurate family history.
The AIOM guidelines, in the context of female cancers, recommend referring patients to CGO (Oncogenetic Counseling).
GENOMICA offers free oncogenetic counseling upon medical referral.
For further information, our team is at your disposal.
Contact Genomica
See you soon with new initiatives in the field of genetics.
The Genomica Team
Pink October represents a valuable opportunity to strengthen cancer prevention and update clinical practice according to the most recent sector guidelines (AIOM and NCCN).
Testing limited only to BRCA1 and BRCA2 genes is not sufficient
The international guidelines (NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, v.1.2026) highlight the importance of extending genetic testing beyond BRCA1/2, including other genes with high clinical impact. Alterations in these genes are associated with a significant increase in cancer risk and have direct implications for surveillance and prevention.
Among the most relevant:
đź“ŤPALB2: breast cancer risk comparable to BRCA2.
đź“ŤPTEN: associated with Cowden syndrome, with high breast cancer risk.
đź“ŤBRIP1: correlated with increased ovarian cancer risk.
The most recent AIOM recommendations also emphasize that the screening methodology for cancer susceptibility must allow the detection of both point variants and genomic rearrangements of BRCA1 and BRCA2.
These rearrangements, not identifiable by NGS alone, represent about 10–15% of pathogenic variants. Integration with the MLPA technique, in case of a negative first-level NGS test, is therefore essential to ensure a complete genetic diagnosis.
Special Offer – Pink October
Throughout the month of October, on the occasion of the breast cancer prevention campaign, GENOMICA offers the possibility to perform the OncoAdvance Risk BRCA Plus test at a special discounted price.
OncoAdvance Risk BRCA Plus analyzes the following genes: BRCA1, BRCA2, PALB2, PTEN, BRIP1.
Study of BRCA1 and BRCA2 rearrangements with MLPA technique
In the event of a negative OncoAdvance Risk BRCA Plus test result, it is possible to integrate the analysis of BRCA1 and BRCA2 rearrangements with the MLPA technique.
This strategy makes it possible to offer patients a complete genetic evaluation in line with the most recent recommendations, ensuring optimized prevention and management pathways also for at-risk family members.
The choice of genes to be analyzed must be guided by an accurate family history.
The AIOM guidelines, in the context of female cancers, recommend referring patients to CGO (Oncogenetic Counseling).
GENOMICA offers free oncogenetic counseling upon medical referral.
For further information, our team is at your disposal.
Contact Genomica
See you soon with new initiatives in the field of genetics.
The Genomica Team